Stockscreener 앱 받기
22.20
1.03%
-0.23
시간 외 거래:
22.55
0.35
+1.58%
전일 마감가:
$22.43
열려 있는:
$22.55
하루 거래량:
1.28M
Relative Volume:
1.08
시가총액:
$1.29B
수익:
$11.13M
순이익/손실:
$-114.59M
주가수익비율:
-9.5979
EPS:
-2.313
순현금흐름:
$-113.96M
1주 성능:
-7.81%
1개월 성능:
-16.89%
6개월 성능:
-15.62%
1년 성능:
+124.24%
1일 변동 폭
$21.82
$22.70
1주일 범위
$21.64
$24.57
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
22.20 | 1.30B | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $62 - Moomoo
Cantor Fitzgerald reiterates Overweight on Capricor stock ahead of FDA decision - Investing.com Canada
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy - MSN
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus - Sahm
Capricor Sinks After FDA Rejects Drug for Muscle Disease - MSN
Enterprise value to EBITDA forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR - TradingView
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Is In A Strong Position To Grow Its Business - Moomoo
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
CAPRCapricor Therapeutics Inc Volatility & Greeks - Finviz
Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal - Sahm
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
(CAPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Capricor’s positive 5-year data for DMD treatment comes with a regulatory catch – CAPR stock slides 11% - MSN
July meeting date set for FDA, developer to talk deramiocel for DMD - Muscular Dystrophy News
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review - Stocktwits
Securities Class Action Lawsuit Filed Against Capricor Therapeuti - The National Law Review
Capricor Therapeutics EVP Karen Krasney sells $732,158 in stock By Investing.com - Investing.com India
Capricor CFO Bergmann sells $732k in shares By Investing.com - Investing.com Australia
Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
Capricor Therapeutics EVP Karen Krasney sells $732,158 in stock - Investing.com
Capricor (NASDAQ: CAPR) EVP exercises options and sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor (NASDAQ: CAPR) CFO sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor Therapeutics Insiders Sold Shares Worth Over $1.5M - TradingView
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $60 - Moomoo
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell 3000E Index - marketscreener.com
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your - The National Law Review
Capricor Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Litvack Frank - Moomoo
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell Microcap Index - marketscreener.com
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Class Action Alert: Levi & Korsinsky Reminds Capricor (CAPR) Investors of September 15, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shar - The National Law Review
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action - The National Law Review
Capricor Therapeutics Faces Stock Drop Ahead of FDA Advisory Meeting - Intellectia AI
Capricor Therapeutics Announces FDA Advisory Committee Meeting for Deramiocel Cell Therapy in Duchenne Muscular Dystrophy – Minichart - Minichart
Capricor Therapeutics to Face FDA Advisory Panel on BLA for Deramiocel; PDUFA Aug 22 - TradingView
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Capricor Therapeutics Inc 주식 (CAPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Option Exercise |
3.18 |
24,100 |
76,638 |
35,323 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
11,223 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
31,047 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
30,947 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
30,547 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
11,723 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
11,623 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
11,223 |
1.18%
2.48%
자본화:
|
볼륨(24시간):